Long-term maintenance therapy for postcardiac transplant monoclonal lymphoproliferative disorder: Caveat mammalian target of rapamycin

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1893-1899

  Khalpey, Z ^a   Miller, D V ^a   Schmitto, J D ^b   Kushwaha, S S ^a  

^a MAYO CLINIC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN KAPPA CHAIN; MAMMALIAN TARGET OF RAPAMYCIN; OKT 3; PRAVASTATIN; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EPSTEIN BARR VIRUS; HEART GRAFT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; POSTOPERATIVE PERIOD; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RELAPSE; REMISSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; VIREMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CALCINEURIN; CYCLOSPORINE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 79959486507     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.033     Document Type: Article

References (33)

1. J.D. Schmitto, M. Grossmann, and E. Kubbe Norman Edward Shumwaypioneer of cardiac surgery (February 9, 1923 to February 10, 2006) Herz 33 2008 386
2. M. Kass, and H. Haddad Cardiac allograft vasculopathy: pathology, prevention and treatment Curr Opin Cardiol 21 2006 132
3. S.S. Kushwaha, J. Narula, and N. Narula Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts Am J Cardiol 82 1998 1377
4. M.J. Weiss, J.C. Madsen, and B.R. Rosengard Mechanisms of chronic rejection in cardiothoracic transplantation Front Biosci 13 2008 2980
5. S.K. Takemoto, A. Zeevi, and S. Feng National conference to assess antibody-mediated rejection in solid organ transplantation Am J Transplant 4 2004 1033
6. S. Ho, N. Clipstone, and L. Timmermann The mechanism of action of cyclosporin A and FK506 Clin Immunol Immunopathol 80 3 Pt2 1996 S40
7. I. Kutschka, K. Pethig, and W. Harringer Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy J Heart Lung Transplant 23 2004 1260
8. F. Gustafsson, and H.J. Ross Proliferation signal inhibitors in cardiac transplantation Curr Opin Cardiol 22 2007 111
9. E. Raichlin, Z. Khalpey, and W. Kremers Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients Transplantation 84 2007 467
10. E. Raichlin, J.H. Bae, and Z. Khalpey Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation Circulation 116 2007 2726
11. N.L. Harris Lymphoma classificationfrom controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms Ann Oncol 11 suppl 1 2000 3
12. B.P. Nelson Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24 2000 375
13. G. Opelz, and R. Henderson Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients Lancet 342 1993 1514
14. L.J. Swinnen, M.R. Costanzo-Nordin, and S.G. Fisher Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients N Engl J Med 323 1990 1723
15. D.E. Tsai, L. Douglas, and C. Andreadis EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial Am J Transplant 2008
16. M. El-Salem, P.N. Raghunath, and M. Marzec Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders Lab Invest 87 2007 29
17. H. Bonatti, D. Hoefer, and H. Rogatsch Successful management of recurrent Epstein-Barr virus-associated multilocular leiomyosarcoma after cardiac transplantation Transplant Proc 37 2005 1839
18. B. Cullis, R. D'Souza, and P. McCullagh Sirolimus-induced remission of posttransplantation lymphoproliferative disorder Am J Kidney Dis 47 2006 e67
19. J.S. Zaltzman, R. Prasad, and K. Chun Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus Nephrol Dial Transplant 20 2005 1748
20. C. Jimenez-Rivera, Y. Avitzur, and A.H. Fecteau Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma Pediatr Transplant 8 2004 243
21. J. Pascual Post-transplant lymphoproliferative disorderthe potential of proliferation signal inhibitors Nephrol Dial Transplant 22 suppl 1 2007 i27
22. C. Ponticelli Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 21 2008 2
23. I.M. Ghobrial, T.M. Habermann, and M.J. Maurer Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders J Clin Oncol 23 2005 7574
24. L.J. Swinnen, G.M. Mullen, and T.J. Carr Aggressive treatment for postcardiac transplant lymphoproliferation Blood 86 1995 3333
25. T.E. Starzl Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1 1984 583
26. J.S. Knight Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center J Clin Oncol 27 2009 3354
27. S. Choquet Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study Blood 107 2006 3053
28. A.M. Evens Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era J Clin Oncol 28 2010 1038
29. D.E. Tsai Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene Am J Transplant 5 2005 2070
30. J. Andrassy, C. Graeb, and M. Rentsch mTOR inhibition and its effect on cancer in transplantation Transplantation 80 2005 S171
31. M. Guba Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
32. A.P. Monaco The role of mTOR inhibitors in the management of posttransplant malignancy Transplantation 87 2009 157
33. B.D. Kahan Low incidence of malignancy among sirolimus/cyclosporine- treated renal transplant recipients Transplantation 80 2005 749